Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
MDT 
Medtronic PLC (MDT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/03/2025: MDT (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
32 Analysts rated it
Highly popular stock, broad analyst coverage, trusted insights, strong investor interest.
1 Year Target Price $96.58
1 Year Target Price $96.58
| 12 | Strong Buy |
| 5 | Buy |
| 13 | Hold |
| 1 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -6.62% | Avg. Invested days 34 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/03/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 113.25B USD | Price to earnings Ratio 24.48 | 1Y Target Price 96.58 |
Price to earnings Ratio 24.48 | 1Y Target Price 96.58 | ||
Volume (30-day avg) 32 | Beta 0.81 | 52 Weeks Range 73.52 - 94.71 | Updated Date 07/4/2025 |
52 Weeks Range 73.52 - 94.71 | Updated Date 07/4/2025 | ||
Dividends yield (FY) 3.26% | Basic EPS (TTM) 3.61 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 13.9% | Operating Margin (TTM) 17.09% |
Management Effectiveness
Return on Assets (TTM) 4.41% | Return on Equity (TTM) 9.51% |
Valuation
Trailing PE 24.48 | Forward PE 15.85 | Enterprise Value 132661047980 | Price to Sales(TTM) 3.38 |
Enterprise Value 132661047980 | Price to Sales(TTM) 3.38 | ||
Enterprise Value to Revenue 3.96 | Enterprise Value to EBITDA 14.39 | Shares Outstanding 1281260032 | Shares Floating 1279163429 |
Shares Outstanding 1281260032 | Shares Floating 1279163429 | ||
Percent Insiders 0.27 | Percent Institutions 86.84 |
Upturn AI SWOT
Medtronic PLC
Company Overview
History and Background
Medtronic was founded in 1949 by Earl Bakken and Palmer Hermundslie as a medical equipment repair shop. It evolved into a pioneering medical technology company, notably developing the first battery-powered wearable pacemaker in 1957. Throughout its history, Medtronic has focused on innovative medical solutions, growing through acquisitions and organic expansion.
Core Business Areas
- Cardiovascular Portfolio: This segment focuses on products and therapies for cardiac rhythm management, coronary and structural heart disease, and aortic, peripheral vascular, and venous disorders. Includes pacemakers, defibrillators, heart valves, and stents.
- Medical Surgical Portfolio: Offers surgical technologies, including robotic-assisted surgery systems, advanced energy instruments, surgical staplers, and gastrointestinal diagnostics and therapies.
- Neuroscience Portfolio: Focuses on therapies for neurological and spinal conditions, including neuromodulation, spinal implants, and neurosurgery products.
- Diabetes Portfolio: Develops and markets insulin pumps, continuous glucose monitoring (CGM) systems, and related diabetes management solutions.
Leadership and Structure
Geoff Martha is the Chairman and CEO of Medtronic. The company operates with a portfolio-based structure, with each portfolio led by a president who reports to the CEO. There is also a functional structure with executive vice presidents leading key areas like finance, strategy, and operations.
Top Products and Market Share
Key Offerings
- Pacemakers: Medtronic is a leading manufacturer of pacemakers, devices that help regulate heart rhythm. Competitors include Abbott (ABT) and Boston Scientific (BSX). Medtronic holds a significant market share, but precise percentage fluctuates based on the specific market segment and year. Medtronic's Cardiovascular Portfolio revenue was $11.3 billion in FY2023.
- Insulin Pumps (MiniMed Series): These pumps deliver insulin to people with diabetes. Competitors include Dexcom (DXCM), Insulet (PODD), and Tandem Diabetes Care (TNDM). Market share varies, but Medtronic is a major player in the insulin pump market. Diabetes Portfolio revenue was $2.3 billion in FY2023.
- Spinal Implants: Medtronic offers a range of spinal implants for treating spinal disorders. Competitors include Stryker (SYK) and Johnson & Johnson (JNJ). Medtronic is a major player in this space with Neurosience Portfolio revenue of $9.6 billion in FY2023.
- Robotic-Assisted Surgery System (Hugo RAS): A robotic surgical system aiming to compete with Intuitive Surgical (ISRG). The product is relatively new to market and gaining adoption. Specific market share data is still evolving. Medical Surgical Portfolio revenue was $8.5 billion in FY2023.
Market Dynamics
Industry Overview
The medical device industry is characterized by innovation, regulation, and increasing demand driven by an aging population and the prevalence of chronic diseases. Competition is intense, with companies vying for market share through product development and strategic acquisitions.
Positioning
Medtronic is one of the largest medical device companies in the world, with a broad portfolio of products and a global presence. Its competitive advantages include its scale, established brand, and extensive distribution network.
Total Addressable Market (TAM)
The global medical device market is projected to reach over $600 billion by 2030. Medtronic is positioned to capture a significant portion of this TAM through its diverse product offerings and global reach.
Upturn SWOT Analysis
Strengths
- Global Presence
- Diversified Product Portfolio
- Strong Brand Recognition
- Significant R&D Investment
- Established Distribution Network
Weaknesses
- Large Bureaucracy
- Slow Decision-Making
- Integration Challenges from Acquisitions
- Dependence on Mature Markets
- Product Recalls and Regulatory Scrutiny
Opportunities
- Emerging Markets Growth
- Technological Advancements (e.g., AI, Robotics)
- Expanding Healthcare Access
- Strategic Partnerships
- Development of Minimally Invasive Procedures
Threats
- Increased Competition
- Pricing Pressure
- Regulatory Changes
- Economic Downturns
- Product Liability Litigation
Competitors and Market Share
Key Competitors
- JNJ
- BSX
- ABT
- ISRG
- SYK
Competitive Landscape
Medtronic is a leader with a comprehensive portfolio. Its scale offers an advantage, but competitors are innovating rapidly in specific areas. Medtronic needs to maintain agility and integration efficiency to compete effectively.
Major Acquisitions
Intercept Vascular Inc.
- Year: 2024
- Acquisition Price (USD millions): 350
- Strategic Rationale: Accelerates Medtronic's entry into the Left Atrial Appendage (LAA) Embolization market, which is expected to grow rapidly in the next 5 years.
Affera, Inc.
- Year: 2023
- Acquisition Price (USD millions): 936
- Strategic Rationale: Expanded Medtronic's cardiac ablation portfolio with differentiated technologies for atrial fibrillation and other arrhythmias.
Growth Trajectory and Initiatives
Historical Growth: Medtronic has grown steadily over the past decades through organic growth and acquisitions. Growth has slowed somewhat in recent years due to economic conditions and increased competition.
Future Projections: Analysts project moderate revenue growth for Medtronic in the coming years, driven by new product launches and expansion into emerging markets. EPS is expected to grow at a faster rate due to cost-cutting initiatives.
Recent Initiatives: Medtronic is focused on developing new technologies such as robotic-assisted surgery and AI-powered diagnostics. The company is also expanding its presence in emerging markets and investing in digital health solutions.
Summary
Medtronic is a large and established medical device company with a diversified portfolio, but faces challenges. Strengths include global reach, dividend history and financial standing. Key areas for Medtronic to focus on are efficient integration of acquisitions, navigating increased competition, and innovating for growth markets.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Medtronic PLC SEC Filings
- Analyst Reports
- Industry Publications
- Company Website
Disclaimers:
The information provided is for informational purposes only and does not constitute investment advice. Market data is subject to change. Financial figures are based on the most recent available data and may be subject to revision.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Medtronic PLC
Exchange NYSE | Headquaters - | ||
IPO Launch date 1978-01-13 | Chairman of the Board & CEO Mr. Geoffrey Straub Martha | ||
Sector Healthcare | Industry Medical Devices | Full time employees 95000 | Website https://www.medtronic.com |
Full time employees 95000 | Website https://www.medtronic.com | ||
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems and sensors, and InPen, a smart insulin pen. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.